Trial Profile
An Open Label, Long Term Safety Trial of BI 65513 (SPESOLIMAB) Treatment in Patients With Moderate to Severely Active Ulcerative Colitis Who Have Completed Previous BI 655130 Trials
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Sep 2023
Price :
$35
*
At a glance
- Drugs Spesolimab (Primary) ; Spesolimab (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 24 May 2023 This trial has been discontinued in Austria (End Date: 03 May 2023), according to European Clinical Trials Database record.
- 15 May 2023 Status changed from active, no longer recruiting to completed.
- 17 Apr 2023 Planned End Date changed from 22 Jun 2023 to 3 May 2023.